December 4, 2023

Drugmaker Eli Lilly & Co. mentioned Monday {that a} second drug that modestly slows the development of Alzheimer’s illness may very well be accepted by the top of this 12 months.

The producer mentioned donanemab considerably slowed cognitive and practical decline in individuals with early symptomatic Alzheimer’s illness, with practically half of the individuals at an earlier stage of illness on the drug with no medical development after one 12 months. 

Eli Lilly beforehand introduced that donanemab met the first and all cognitive and practical secondary endpoints within the Section 3 examine. 

Submission to the Meals and Drug Administration for conventional approval was accomplished final quarter and submissions to different world regulators are presently ongoing. 


Eli Lilly headquarters in Indianapolis, Indiana, on Wednesday, Might 3, 2023.  (Photographer: AJ Mast/Bloomberg through Getty Pictures / AP Newsroom)

The corporate mentioned the bulk might be accomplished by 12 months’s finish. 

“If accepted, we consider donanemab can present clinically significant advantages for individuals with this illness and the potential for finishing their course of therapy as early as 6 months as soon as their amyloid plaque is cleared. We should proceed to take away any obstacles in entry to amyloid-targeting therapies and diagnostics in an already advanced healthcare ecosystem for Alzheimer’s illness,” mentioned Anne White, govt vp of Eli Lilly.

The examine – revealed by the Journal of the American Medical Affiliation – discovered that donanemab slowed Alzheimer’s illness development by 35% relative to placebo in a 19-month-long trial that included greater than 1,700 early-stage individuals ages 60-85.

Examine individuals on the earliest stage of the illness had a fair larger profit, and there was a 60% slowing of decline in comparison with placebo.

A sign for the Food And Drug Administration is seen outside of the headquarters

An indication for the Meals And Drug Administration is seen outdoors of the headquarters on July 20, 2020, in White Oak, Maryland.  ((Picture by Sarah Silbiger/Getty Pictures) / AP Newsroom)


If cleared, donanemab could be solely the second Alzheimer’s therapy convincingly proven to delay the illness, following the FDA’s approval of Biogen and Eisai’s Leqembi.

A man receives a PET scan

Jay Reinstein, who suffers from Alzheimer’s, prepares to obtain a PET scan at MedStar Georgetown College Hospital in Washington, D.C., on June 20, 2023.  ((Picture by Michael Robinson Chávez/The Washington Put up through Getty Pictures) / AP Newsroom)

Each donanemab and Leqembi are lab-made antibodies, administered intravenously, that concentrate on sticky amyloid buildup within the mind. Notably, the medication additionally include a severe security concern – mind swelling or bleeding that, within the Lilly examine, was linked to a few deaths.


A couple of quarter of donanemab recipients confirmed proof of mind swelling, and about 20% had microbleeds.

Greater than 90% of the examine’s individuals had been White, leaving little knowledge about how different populations may reply to the drug.

The Related Press contributed to this report.